Publications by authors named "Rikke Boedker Holmstroem"
Article Synopsis
- The study investigated the efficacy and safety of a vaccine combining Bcl-XL-derived peptides and the adjuvant CAF09b in patients with hormone-sensitive prostate cancer, aiming to enhance immune responses against cancer cells.
- Twenty patients were divided into two groups: one received intramuscular (IM) vaccinations followed by intraperitoneal (IP), while the other group received IP first and then IM, monitoring safety and immune response.
- Results showed no serious adverse events and indicated that patients receiving the IP first demonstrated stronger and earlier immune responses, with significant activation of CD4 and CD8 T cell markers after vaccination.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can cause various immune-related side effects affecting different organs, with colitis being common and enteritis rare.
- A case was presented of a metastatic melanoma patient who experienced severe ICI-induced enterocolitis that didn't respond to conventional treatments but showed partial improvement from fecal microbiota transplantation and a complete response to tofacitinib.
- The findings suggest that tofacitinib could be an effective treatment option for patients suffering from severe diarrhea due to ICI-induced colitis or enteritis.
Background: Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation of arginase-1-specific T cells may convert the immunosuppressive tumor microenvironment and induce or strengthen local Th1 inflammation.
View Article and Find Full Text PDFBackground: Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis.
View Article and Find Full Text PDFAnti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study ( https://clinicaltrials.
View Article and Find Full Text PDF